Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 126


Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.

Akin-Akintayo OO, Jani AB, Odewole O, Tade FI, Nieh PT, Master VA, Bellamy LM, Halkar RK, Zhang C, Chen Z, Goodman MM, Schuster DM.

Clin Nucl Med. 2016 Oct 5.


Neurovascular bundle-sparing radiotherapy for prostate cancer using MRI-CT registration: A dosimetric feasibility study.

Cassidy RJ, Yang X, Liu T, Thomas M, Nour SG, Jani AB.

Med Dosim. 2016 Oct 13. pii: S0958-3947(16)30079-6. doi: 10.1016/j.meddos.2016.08.003.


Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.

Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):206-13. doi: 10.1016/j.ijrobp.2016.04.023. Epub 2016 Apr 30.


Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.


In regard to Wu and Vapiwala et al.

Meyer JE, Dilling TJ, Amdur RJ, Strasser JF, Tendulkar R, Lee WR, Jani AB, Elshaikh M, Poppe MM, Takita C, Currey A, Cheng SK, Jagsi R, Kuo JV, Chen AM, Dragun AE, Bradley K, Beriwal S, Smith RP, Chen RC, Rosenzweig K, Kim S, Mehta K.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):858-9. doi: 10.1016/j.ijrobp.2015.12.001. No abstract available.


Results of the 2014 Survey of the Association of Directors of Radiation Oncology Programs (ADROP).

Jani AB, Marshall D, Vapiwala N, Davis SB, Langer M.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e673-8. doi: 10.1016/j.prro.2015.06.007. Epub 2015 Jun 21.


Locoregional prostate cancer treatment pattern variation in independent cancer centers: policy effect, patient preference, or physician incentive?

Camarata AS, Nickleach DC, Jani AB, Rossi PJ.

Health Serv Insights. 2015 Apr 15;8:1-8. doi: 10.4137/HSI.S24092. eCollection 2015.


Bladder preservation strategies.

Jani AB, Efstathiou JA, Shipley WU.

Hematol Oncol Clin North Am. 2015 Apr;29(2):289-300, ix. doi: 10.1016/j.hoc.2014.10.004. Epub 2014 Dec 15. Review.


Role of radiation and androgen deprivation therapy for advanced prostate cancer.

Jani AB, Rossi PJ.

Curr Probl Cancer. 2015 Jan-Feb;39(1):41-7. doi: 10.1016/j.currproblcancer.2014.11.007. Epub 2014 Nov 25. Review. No abstract available.


Video-based educational tool improves patient comprehension of common prostate health terminology.

Wang DS, Jani AB, Sesay M, Tai CG, Lee DK, Echt KV, Goodman MG, Kilbridge KE, Master VA.

Cancer. 2015 Mar 1;121(5):733-40. doi: 10.1002/cncr.29101. Epub 2014 Nov 12.


Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy.

Yang X, Rossi P, Ogunleye T, Marcus DM, Jani AB, Mao H, Curran WJ, Liu T.

Med Phys. 2014 Nov;41(11):111915. doi: 10.1118/1.4897615.


Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis.

Odewole OA, Oyenuga OA, Tade F, Savir-Baruch B, Nieh PT, Master V, Chen Z, Wang X, Jani AB, Bellamy LM, Halkar RK, Goodman MM, Schuster DM.

Mol Imaging Biol. 2015 Apr;17(2):277-83. doi: 10.1007/s11307-014-0797-1.


The impact of multiparametric pelvic magnetic resonance imaging on risk stratification in patients with localized prostate cancer.

Marcus DM, Rossi PJ, Nour SG, Jani AB.

Urology. 2014 Jul;84(1):132-7. doi: 10.1016/j.urology.2014.03.012. Epub 2014 Apr 29.


Clinically Significant Difference in Prostate Localization Using Daily Cone Beam CT (CBCT) and Electromagnetic Transponders.

Khan MK, Das S, Ogunleye T, Jani AB, Rossi P, Shelton J, Liu T.

Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S15. doi: 10.1016/j.prro.2013.01.056. Epub 2013 Mar 25. No abstract available.


Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate.

Hall WA, Colbert L, Nickleach D, Shelton J, Marcus DM, Switchenko J, Rossi PJ, Godette K, Cooper S, Jani AB.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):e157-64. doi: 10.1016/j.prro.2013.01.003. Epub 2013 Feb 21.


A New CT Prostate Segmentation for CT-Based HDR Brachytherapy.

Yang X, Rossi P, Ogunleye T, Jani AB, Curran WJ, Liu T.

Proc SPIE Int Soc Opt Eng. 2014;9036:90362K.


Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

Schuster DM, Nieh PT, Jani AB, Amzat R, Bowman FD, Halkar RK, Master VA, Nye JA, Odewole OA, Osunkoya AO, Savir-Baruch B, Alaei-Taleghani P, Goodman MM.

J Urol. 2014 May;191(5):1446-53. doi: 10.1016/j.juro.2013.10.065. Epub 2013 Oct 19.


The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate.

Hall WA, Nickleach DC, Master VA, Prabhu RS, Rossi PJ, Godette K, Cooper S, Jani AB.

Cancer. 2013 Sep 15;119(18):3272-9. doi: 10.1002/cncr.28185. Epub 2013 Jul 1.


Therapeutic options for a rising PSA after radical prostatectomy.

Carthon BC, Marcus DM, Herrel LA, Jani AB, Rossi PJ, Canter DJ.

Can J Urol. 2013 Jun;20(3):6748-55. Review.


Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy.

Wang Y, Liu T, Rossi PJ, Watkins-Bruner D, Hsiao W, Cooper S, Yang X, Jani AB.

J Sex Med. 2013 Aug;10(8):2108-14. doi: 10.1111/jsm.12215. Epub 2013 Jun 6.

Items per page

Supplemental Content

Support Center